Work

Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.17_suppl.lba9009

Authors: Joshua K. Sabari, Alexander I. Spira, Rebecca Suk Heist, Pasi A. Janne, Jose M. Pacheco, Jared Weiss, Shirish M. Gadgeel, Hirak Der-Torossian, Karen Velastegui, Thian Kheoh, James G Christensen, Marcelo Vailati Negrao

Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Virginia Cancer Specialists, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Colorado Anschutz, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Henry Ford Health, Henry Ford Hospital, Mirati Therapeutics (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4293083660

Cites:

Cited by: 26

Related to: 10